Lend Your Support to CMS for Better Access to Obesity Medicines
The docket is open for you to lend your support until January 27. The Center for Medicare and Medicaid Services (CMS) is proposing to open up access to obesity medicines in both of the programs they oversee. This is something that we – with virtually every advocate for obesity care – have been seeking for more than a decade.
In essence, CMS is proposing that drug benefits for both Medicare and Medicaid should treat obesity medicines just like any other drug for a chronic disease and provide coverage. Until now, Medicare has denied coverage across the board. Coverage under Medicaid has been optional and unreliable from state to state.
So now is the time to lend your support to perhaps the most important change in obesity policy we will see in our lifetimes.
Three Important Points
In this proposal are three important points that lay the groundwork for better obesity care.
First, CMS is saying very clearly that obesity is a complex, chronic disease that merits treatment just like any other chronic disease.
Next is the concept that these drugs serve the purpose of treating the obesity. Thus, exclusionary language about denying coverage for drugs used only for weight loss does not apply when a physician is treating obesity.
Finally is flexibility in defining obesity. The agency leaves room for health plans to define the disease and criteria for covering it as standards for care evolve.
Make Your Voice Heard
This proposal may well be the most important advance in policy for obesity care that we will ever witness. CMS sets a standard for health plans that many other health insurance plans follow. Going from denial for any coverage in Medicare to treating obesity medicines like medicines for any other disease is huge. On top of that, setting aside arbitrary denial of coverage for obesity medicines in Medicaid can do a lot to ease the disparities in access to care that are so glaring right now.
So take a minute and share your thoughts with CMS on this change. Make your voice heard. Encourage your friends, family, and colleagues to do the same. This is big.
You can find the docket and submit your comments here. Simply click on the “comment” button on that page. For more perspective, tips, and resources on maximizing the impact of your comments, click here.
The Artist’s Letter Rack, painting by William Michael Harnett / WikiArt
Subscribe by email to follow the accumulating evidence and observations that shape our view of health, obesity, and policy.
January 9, 2025
January 09, 2025 at 8:19 am, Adva Weinerman said:
I wish to convey my heartfelt thanks to your blog. I had been taking Ozempic for six months until my medical insurance care authorities prohibited those without diabetes from continuing with it (even if pre diabetes) though they did not pay for it. Consequentially I moved to Wegovy and have been taking it for additional 6 month, (1mg). I have not been able to lose any weight no matter how much I dieted and tried most diets known. I have been losing weight albeit very slowly, but losing. I am going to keep at it for as long as I can. I have no negative side effects other than hair loss. That is why I do not take higher dosage. But your fact airing so to speak in your blog kept me going – I read all your daily issues. I was surprised to learn today that in our private pharmacy there was a rather large price deduction. My private insurance also paid for some of my previous expenditure so you see, there is hope. Keep your good work.
January 09, 2025 at 3:38 pm, Ted said:
Thanks, Adva. We all need encouragement. Hang in there.
January 10, 2025 at 8:07 am, Debra GreenfieldMD said:
“Americans suffering with Obesity deserve to be treated with medications that are covered like all of the other disease’s that they suffer from. It does not make any sense that medications to treat diabetes and hypertension are covered but Obesity is not. The double standard of discriminating against patients suffering from the disease obesity should come to an end. Please change this policy”.